/PRNewswire/ BioSpace, the leader in biopharma news and careers today released a report that found 80% of unvaccinated respondents would resign if their.
/PRNewswire/ BioSpace, the leader in biopharma news and careers today released a report that found 80% of unvaccinated respondents would resign if their.
Published: Apr 12, 2021
SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has granted a conditional approval to toripalimab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. This is the third approved indication for toripalimab in China. In December 2018, the NMPA granted a conditional approval to toripalimab for the second-line treatment of unresectable or metastatic melanoma. In February 2021, the NMPA granted a conditional approval to toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) after fail
Gluten Tolerance Test Kits Market: Increase in Prevalence of Celiac Disease to Drive the Market - read this article along with other careers information, tips and advice on BioSpace
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV TramadolThe FDA Has Not Provided a Decision Regarding the NDA - read this article along with other careers information, tips and advice on BioSpace